Article Sidebar

Submitted
Apr 26, 2021
Published
Apr 26, 2021
Download
PDF
Statistic
Read Counter : 35 Download : 24

Main Article Content

Abstract

Tuberculosis (TB) still remain a major challenging global health problem. India is one the high TB burden country, adding to 26 per cent of the worldwide TB burden. During the 20th century, TB became treatable and the therapeutic success of short-course chemotherapy was a break through. In the early 1980s, human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) pandemic resulted in a resurgence of TB globally with more complications and challenges like occurrence of multidrug-resistant and extensively drug-resistant TB (M/XDR-TB). Atypical clinical presentation still poses a challenge. While treatment of TB and HIV-TB co-infection has become simpler, efforts are on to shorten the treatment duration. However, drug toxicities, adverse drug reactions and drug-drug interactions still possess a significant challenge. Hurdles like the lack of adequate coverage, low economy and weak health services limit access to high-quality tuberculosis care in some of the countries. Further, many public and private health-care providers remain delinked from national tuberculosis control efforts. In addition, tuberculosis is a disease of the poor and the absence of universal health coverage aggravates the economic burden of TB on the poor. Even though the advancements in tuberculosis control over the past two decades are strong, relatively high effort is needed to wipe out the pandemic. A pursuit for novel biomarkers for predicting a durable cure, relapse, discovery/repurposing of newer anti-TB drugs, development of newer vaccines continues to attain the goal of eliminating TB altogether by 2050. The present review focuses on the global and Indian tuberculosis situation. It emphasizes the epidemiological situation in India and the burden of disease in the nation over time.

Keywords

Tuberculosis (TB) Drug resistance Multi drug resistance TB

Article Details

How to Cite
Keerthy J, Hrishi V, Sagarika B.H, Lakshmi I, Prasanth Kumar S, Dr. K. Sattanathan, & Dr. R. Sambathkumar. (2021). An overview on the national burden of tuberculosis and its current status. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(4), 428-434. https://doi.org/10.61096/ijrpp.v4.iss4.2015.428-434
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Global tuberculosis report 2015.Tuberculosis. www.who.int/tb/publications/global_report/en/. Accessed October 25, 2015.
  2. [2]. Annual TB Report 2015.Tuberculosis control in the South-East Asia Region 2015. www.searo.who.int/tb/en/ . Accessed October 25, 2015.
  3. [3]. RNTCP TB Report 2014. www.tbcindia.nic.in. Published on March 10, 2014. Accessed October 26, 2015.
  4. [4]. Tuberculosis. http://www.who.int/mediacentre/factsheets/fs104/en/. Updated October 2015. Accessed October 26, 2015.
  5. [5]. Sharma SK and Mohan A. Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium. Indian J Med Res 137, March 2013, pp 455-493
  6. [6]. Jain S, Rodrigues C, Mehta A, Udwadia ZF. High prevalence 54. Of XDR-TB from a tertiary care hospital in India. Am J Respir Crit Care Med 2007; 175: A510.
  7. [7]. Datta BS, Hassan G, Kadri SM, Qureshi W, Kamili MA, Singh 55. H, et al. Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries 2009; 4: 19-23.
  8. [8]. Murray M, Oxlade O, Lin HH. Modeling social, environmental 56. And biological determinants of tuberculosis. Int J Tuberc Lung Dis 2011; 15 (Suppl 2): S64-70.
  9. [9]. Lawn SD, Zumla AI. Tuberculosis. 57. Lancet 2011; 378: 57-72.
  10. [10]. Möller M, de Wit E, Hoal EG. Past, present and future 58. Directions in human genetic susceptibility to tuberculosis. FEMS Immunol Med Microbiol 2010; 58: 3-26.
  11. [11]. Najmi N, Kaur G, Sharma SK, Mehra NK. Human Toll-like 59. Receptor 4 polymorphisms TLR4 Asp299Gly and Thr399Ile influence susceptibility and severity of pulmonary tuberculosis in the Asian Indian population. Tissue Antigens 2010; 76: 102-9.
  12. [12]. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, 65. Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151: 129-35.
  13. [13]. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam 66. RA, Jacobs WR Jr, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction fragment length polymorphisms. N Engl J Med 1992; 326: 231-5.
  14. [14]. Modjarrad K, Vermund SH. Effect of treating co-infections on 67. HIV-1 viral load: a systematic review. Lancet Infect Dis 2010; 10: 455-63.
  15. [15]. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi 68. B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-93.
  16. [16]. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, 69. Desmond E, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328: 1137-44.
  17. [17]. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects 70. Of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003; 37: 101-12.
  18. [18]. Sharma S, Rathored J, Ghosh B, Sharma SK. Genetic 60. Polymorphisms in TNF genes and tuberculosis in North Indians. BMC Infect Dis 2010; 10: 165.
  19. [19]. Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary 23. Tuberculosis: new insights into an old disease. Lancet Infect Dis 2005; 5: 415-30.
  20. [20]. Sharma SK, Mohan A, Kadhiravan T. HIV-TB co-infection: 62. Epidemiology, diagnosis & management. Indian J Med Res 2005; 121: 550-67.
  21. [21]. Sharma SK, Mohanan S, Sharma A. Relevance of latent TB 92. Infection in areas of high TB prevalence. Chest 2012; 142:761-73.
  22. [22]. World Health Organization. Global tuberculosis control: WHO 37. Report 2012. WHO/HTM/ TB/2012.6. Geneva: World Health Organization; 2012. Available from: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf, accessed on February 28, 2013.
  23. [23]. Wares DF. Global tuberculosis control: the future prospects.236. In: Sharma SK, Mohan A, editors. Tuberculosis. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2009. p. 874-93.
  24. [24]. Landmark meeting on post-2015 TB targets held in Geneva. 237. Available from: http://www.stoptb.org/news/stories/2013/ns13_012.asp, accessed on February 28, 2013.